Candel Therapeutics Inc. (CADL)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Candel Therapeutics unveils $80M public offering
Candel Therapeutics Inc (NASDAQ:CADL) has announced an $80 million underwritten public offering of its common stock and pre-funded warrants. The offering includes approximately 10 million shares of common stock at $6 per share and approximately 3.33 million pre-funded warrants priced at $5.99 each, representing the public offering price minus a $0.01 per share exercise cost.
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate cancer.
Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight
Candel's phase 3 trial for CAN-2409 in high-risk prostate cancer met its primary endpoint, showing a 14.5% improvement in disease-free survival over placebo. Financially, CADL holds $16.6 million in cash, facing a likely equity raise soon due to high operational expenses and limited cash runway. Despite a phase 2b trial setback in lower-risk prostate cancer, the phase 3 success supports a potential FDA submission by mid-2025.
Biotech Stock Hits 3-Year Highs on Trial Results
Candel Therapeutics Inc (NASDAQ:CADL) is soaring today, up 164% at $12.17 at last glance and earlier hitting a three-year high of $14.60, after the biotech company's prostate cancer immunotherapy treatment, CAN-2409, met its goal in a late-stage study.
Candel Therapeutics Stock Surges Over 100% - Here's Why
On Wednesday, Candel Therapeutics, Inc. CADL announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients.
Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug
Shares of Candel Therapeutics skyrocketed Wednesday after the biotech company's prostate cancer treatment succeeded in a Phase 3 study. The post Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug appeared first on Investor's Business Daily.
Candel Therapeutics reports positive Phase 3 results for CAN-2409 in localized prostate cancer
Candel Therapeutics Inc (NASDAQ:CADL) announced that its experimental immunotherapy, CAN-2409, met its main goal in a Phase 3 trial, significantly improving disease-free survival in patients with localized prostate cancer. The trial showed a 14.5% improvement in disease-free survival (DFS) at 54 months for the CAN-2409 group compared to the control arm and significantly reduced recurrence risk while improving prostate cancer-free survival.
Candel Therapeutics' cancer drug meets late-stage trial goals
Candel Therapeutics said on Wednesday its experimental prostate cancer drug met the main goal of a late-stage trial, sending the company's shares up 64% in premarket trading.
Candel Therapeutics is pushing for a paradigm shift in cancer treatment
Cancer treatment has long been dominated by traditional approaches such as surgery, radiation, and chemotherapy. But in recent years, a wave of innovation has emerged, driven by the promise of immunotherapies that harness the body's own immune system to fight cancer.
Candel Therapeutics CEO: Putting patients first is the key to reframing cancer treatment
In the biopharmaceutical world, where innovation and breakthroughs often dominate headlines, a fundamental question is frequently overlooked: are we truly listening to patients? For Paul Peter Tak CEO of Candel Therapeutics Inc (NASDAQ:CADL), the answer has shaped a career rooted in both scientific discovery and personal resilience.
Candel Therapeutics CEO anticipates 'paradigm shift' in prostate cancer treatment as Q3 work wraps up
Candel Therapeutics Inc (NASDAQ:CADL) CEO Paul Peter Tak expressed optimism for a "paradigm shift" in prostate cancer treatment as the biopharmaceutical company moves closer to phase 2b and phase 3 trial data releases for its lead therapy, CAN-2409. Tak stated the data, expected in the fourth quarter of 2024, could pave the way for new regulatory approvals for CAN-2409 in non-metastatic, localized prostate cancer.
Candel Therapeutics' CAN-3110 offers new hope for melanoma treatment – ICYMI
Candel Therapeutics Inc (NASDAQ:CADL) recently presented insights into its oncolytic virus therapy, CAN-3110, at the Society for Immunotherapy of Cancer (SITC) conference. The company's Chief Scientific Officer, Dr.
